Anteris Technologies Global Corp. elected to discontinue additional development contributions under its Contribution and Stock Purchase Agreement with v2vmedtech, inc., triggering a $400,000 break fee and potential loss of equity interest.
Key takeaways
Company notified v2vmedtech on April 28, 2026, to discontinue contributions after Stage 1 completion during Stage 2.
Required to pay $400,000 break fee to v2v for continued technology development.
No further development contribution obligations under the Agreement.
v2v initial shareholders can elect to buy out Company's equity for aggregate contributions to date or reduce it to capped minority percentage.
Development Agreement terminates upon break fee payment.
Company states no material adverse effect expected on financial position or liquidity.